The synergy between the enhanced antigen presentation and targeted immune response increases the efficacy of CD8+ T cell mediated anti-tumour attacks, which is crucial as standard therapies often fail to distinguish between antiviral and antitumour responses. This evidence concerns the gene CD8A and neoplasm.